Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
UIF (University Industry Foundation), Yonsei University has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The portfolio is managed by 1 distinct examiner within 1 distinct art unit. The concentration in 1 distinct art unit indicates that the university's biotechnological or pharmaceutical innovation is being reviewed by a specific technical division. This single-unit focus can provide a consistent environment for the 1 pending office action.
William Y. Lee is the busiest examiner, handling the 1 pending office action. This single action constitutes the total 1 pending office action for the entity. As the only one of the 1 distinct examiners involved, William Y. Lee is responsible for the entire current workload. The 1 busiest examiner pending action managed by this examiner represents the full extent of the university's active prosecution at the office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, WILLIAM Y | 1 | 47.9% | +34.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18400602 | NOVEL MKRN1 INHIBITOR AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OBESITY OR FATTY LIVER COMPRISING THE SAME | LEE, WILLIAM Y | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18400602 | NOVEL MKRN1 INHIBITOR AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OBESITY OR FATTY LIVER COMPRISING THE SAME | LEE, WILLIAM Y | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18400602 | NOVEL MKRN1 INHIBITOR AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OBESITY OR FATTY LIVER COMPRISING THE SAME | LEE, WILLIAM Y | 1623 | §103§112 | Non-Final OA | — | Pending | Dec 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial